13th Annual World Congress on Inflammation
Dr. Jonathan Zalevsky, SVP, Biology discusses NKTR-214
Lilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize NKTR-358, A Novel Autoimmune Therapy
Nektar Announces Topline Data from Human Abuse Potential Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain
We are focused on using new chemistry approaches to make better medicines to treat cancer, chronic pain and auto-immune disease.